為達最佳瀏覽效果,建議使用 Chrome、Firefox 或 Microsoft Edge 的瀏覽器。

請至Edge官網下載 請至FireFox官網下載 請至Google官網下載
晴時多雲

    限制級
    您即將進入之新聞內容 需滿18歲 方可瀏覽。
    根據「電腦網路內容分級處理辦法」修正條文第六條第三款規定,已於網站首頁或各該限制級網頁,依台灣網站分級推廣基金會規定作標示。 台灣網站分級推廣基金會(TICRF)網站:http://www.ticrf.org.tw

    《TAIPEI TIMES》DNA vaccine research is promising, NHRI says

    From left, National Health Research Institutes (NHRI) Bioproduction Plants Facility director Liu Shih-jen, Enimmune Corp director Lee Tsung-dao, NHRI Institute of Infectious Diseases and Vaccinology director Liao Ching-len and deputy director Chen Hsin-wei attend a news conference yesterday at the Ministry of Health and Welfare in Taipei. 

Photo: Wu Liang-yi, Taipei Times

    From left, National Health Research Institutes (NHRI) Bioproduction Plants Facility director Liu Shih-jen, Enimmune Corp director Lee Tsung-dao, NHRI Institute of Infectious Diseases and Vaccinology director Liao Ching-len and deputy director Chen Hsin-wei attend a news conference yesterday at the Ministry of Health and Welfare in Taipei. Photo: Wu Liang-yi, Taipei Times

    2020/08/11 03:00

    By Lee I-chia / Staff reporter

    The National Health Research Institutes (NHRI) yesterday said that tests of its DNA vaccine against COVID-19 on hamsters was promising, with clinical trials likely to start later this year.

    The institute on July 1 chose the DNA vaccine among its four vaccine development platforms as its main focus and started animal testing, Institute of Infectious Diseases and Vaccinology director Liao Ching-len (廖經倫) said.

    “The vaccine has shown the effect of significantly reducing the viral load and decreasing the damage that the virus caused to the lungs” of hamsters, he said.

    “With the DNA vaccine, we deliver genetic information [a plasmid containing the DNA sequence encoding the antigens against COVID-19] into the human body, and when it enters the cells, the cells produce spike proteins,” Liao said.

    He said it is similar to the actual situation of when someone is infected by the virus, stimulating the body’s immune response.

    In animal testing, the vaccine successfully stimulated the production of neutralizing antibodies, blocking the viral infection, he said.

    Hamsters that did not receive the vaccine lost weight and general vitality, and their viral load remained high, while those that received the vaccine did not lose much weight or vitality and their viral load dropped significantly to 1 percent of the original volume, Liao said.

    He said the research team was “amazed” at the results of animal testing.

    “We hope the experiments can proceed to the first phase of a clinical trial in the fourth quarter this year, finish the third phase of the clinical trial by the third quarter next year, and hit the market as soon as possible,” he said.

    新聞來源:TAIPEI TIMES

    不用抽 不用搶 現在用APP看新聞 保證天天中獎  點我下載APP  按我看活動辦法

    焦點今日熱門

    網友回應

    此網頁已閒置超過5分鐘,請點擊透明黑底或右下角 X 鈕。